Abstract: An aspect of the invention described herein includes a method for a digestion diagnosis of a subject. The method includes obtaining electrogastrogram (EGG), bowel sound and NIRS signals from one or more sensors positioned about an abdominal region of a subject, removing artifacts from the signals to obtain conditioned signal data, and determining a digestion condition or feeding readiness of the subject based at least in part on the conditioned signal data.

Abstract: An aspect of the invention described herein includes a method for a digestion diagnosis of a subject. The method includes obtaining electrogastrogram (EGG), bowel sound and NIRS signals from one or more sensors positioned about an abdominal region of a subject, removing artifacts from the signals to obtain conditioned signal data, and determining a digestion condition or feeding readiness of the subject based at least in part on the conditioned signal data.

Abstract: Isolated Lactobacillus strains are useful in preventing or delaying the development of Type 1 Diabetes (T1D). A probiotic composition comprising the Lactobacillus strains and use of the composition in T1D prevention are provided.

Abstract: The present disclosure is directed to a novel nutritional formula for treating or preventing systemic inflammation in a subject. The nutritional formula comprises a therapeutically effective amount of inactivated Lactobacillus rhamnosus GG (LGG).

Abstract: A children's or infant's nutritional product utilizing or containing one or more inactivated probiotics for preventing or reducing systemic and/or respiratory inflammation in a child or infant.

Abstract: The subject invention provides compositions, and uses thereof, that improve gastrointestinal function. The compositions and methods of the subject invention are particularly advantageous for use with neonates because they can be used to stimulate development of the immature intestine in order to provide an enhanced ability to absorb nutrients and attain a stronger barrier function.

Abstract: The subject invention pertains to materials and methods for diagnosing and/or predicting pathologic infant conditions. A method of the invention comprises obtaining a biological sample from an infant and analyzing the sample to detect at least one protein biomarker of necrotizing enterocolitis (NEC), wherein a patient is diagnosed with NEC or determined to have a likelihood of developing NEC following detection of the biomarker. In another method of the invention, the likelihood of a patient developing NEC is determined. In certain embodiments, treatment is administered to the patient following diagnosis of NEC or determination that the patient has a likelihood of developing NEC.

Abstract: Isolated Lactobacillus strains are useful in preventing or delaying the development of Type 1 Diabetes (T1D). A probiotic composition comprising the Lactobacillus strains and use of the composition in T1D prevention are provided.

Abstract: The subject invention provides dipeptides useful in promoting healthy muscle tissues as well as effective immune responses. The dipeptides of the subject invention are particularly advantageous because they are stable, bioavailable, and can be formulated in an aqueous solution.

Abstract: The subject invention provides dipeptides useful in promoting healthy muscle tissues as well as effective immune responses. The dipeptides of the subject invention are particularly advantageous because they are stable, bioavailable, and can be formulated in an aqueous solution.

Abstract: The subject invention provides compositions, and uses thereof, that improve gastrointestinal function. The compositions and methods of the subject invention are particularly advantageous for use with neonates because they can be used to stimulate development of the immature intestine in order to provide an enhanced ability to absorb nutrients and attain a stronger barrier function.

Abstract: The subject invention provides dipeptides useful in preventing pathological proliferation of blood vessels. The dipeptides of the subject invention are particularly advantageous because they are stable, bioavailable, and can be formulated in an aqueous solution.

Abstract: The subject invention provides for the administration of docosahexaenoic acid in preventing pathological proliferation of blood vessels. The compositions of the subject invention are particularly advantageous because they are stable, bioavailable, and can be formulated in an aqueous solution.

Abstract: The subject invention provides dipeptides useful in promoting healthy muscle tissues as well as effective immune responses. The dipeptides of the subject invention are particularly advantageous because they are stable, bioavailable, and can be formulated in an aqueous solution.

Abstract: The present invention is directed to a novel method for treating or preventing systemic inflammation in a subject. The method administering to the subject a therapeutically effective amount of inactivated LGG.

Abstract: A novel method and product utilizing or containing one or more inactivated probiotics.

Abstract: The subject invention provides dipeptides useful in preventing pathological proliferation of blood vessels. The dipeptides of the subject invention are particularly advantageous because they are stable, bioavailable, and can be formulated in an aqueous solution.

Abstract: The present invention is directed to a novel method for treating or preventing systemic inflammation in a formula-fed infant. The method administering to the infant a therapeutically effective amount of LGG in combination with at least one LCPUFA.

Abstract: The subject invention provides dipeptides useful in preventing pathological proliferation of blood vessels. The dipeptides of the subject invention are particularly advantageous because they are stable, bioavailable, and can be formulated in an aqueous solution.

Abstract: The present invention is directed to a novel method for treating or preventing systemic inflammation in a formula-fed infant. The method comprises administering a therapeutically effective amount of LGG to the infant.